Independent Franchise Partners LLP Sells 3,007,521 Shares of Corteva, Inc. $CTVA

Key Points

• Independent Franchise Partners cut its Corteva holding by 22.5%, selling 3,007,521 shares in the quarter and now owns 10,387,954 shares (about 1.54% of the company) worth roughly $702.5 million, making CTVA its 10th-largest holding.
• Corteva posted Q results with EPS of $0.22 (in line) but revenue of $3.91B that missed estimates, issued FY 2026 guidance of 3.45–3.70 EPS, and carries a MarketBeat consensus of "Moderate Buy" with a $82.90 target.
• Insider Brian Titus sold 8,311 shares at an average of $76.55 (≈$636k), reducing his stake by about 50.7%, while corporate insiders collectively own only 0.14% of the company.

Independent Franchise Partners LLP lessened its holdings in shares of Corteva, Inc. (NYSE:CTVA - Free Report) by 22.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,387,954 shares of the company's stock after selling 3,007,521 shares during the quarter. Corteva accounts for about 4.6% of Independent Franchise Partners LLP's investment portfolio, making the stock its 10th largest holding. Independent Franchise Partners LLP owned approximately 1.54% of Corteva worth $702,537,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Total Investment Management Inc. acquired a new position in Corteva during the second quarter valued at approximately $27,000. Activest Wealth Management increased its position in shares of Corteva by 118.3% in the third quarter. Activest Wealth Management now owns 369 shares of the company's stock worth $25,000 after acquiring an additional 200 shares in the last quarter. True Wealth Design LLC raised its stake in shares of Corteva by 209.5% in the 3rd quarter. True Wealth Design LLC now owns 390 shares of the company's stock valued at $26,000 after acquiring an additional 264 shares during the period. Twin Peaks Wealth Advisors LLC purchased a new position in shares of Corteva in the 2nd quarter valued at $29,000. Finally, Redmont Wealth Advisors LLC acquired a new position in shares of Corteva during the 3rd quarter valued at $29,000. Hedge funds and other institutional investors own 81.54% of the company's stock.

Insider Buying and Selling

In related news, insider Brian Titus sold 8,311 shares of the stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the transaction, the insider owned 8,090 shares of the company's stock, valued at approximately $619,289.50. This represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.14% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Argus upgraded Corteva to a "strong-buy" rating in a report on Friday, January 16th. Wall Street Zen cut Corteva from a "buy" rating to a "hold" rating in a research note on Saturday, February 7th. CICC Research upped their target price on Corteva from $70.00 to $80.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 11th. Royal Bank Of Canada increased their target price on Corteva from $80.00 to $89.00 and gave the company an "outperform" rating in a research note on Thursday, February 5th. Finally, Zacks Research downgraded Corteva from a "strong-buy" rating to a "hold" rating in a report on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $82.90.

Corteva Price Performance

CTVA opened at $79.13 on Friday. Corteva, Inc. has a twelve month low of $53.40 and a twelve month high of $80.90. The firm has a market cap of $53.22 billion, a price-to-earnings ratio of 50.08, a PEG ratio of 2.73 and a beta of 0.72. The company has a current ratio of 1.43, a quick ratio of 0.96 and a debt-to-equity ratio of 0.07. The company has a fifty day simple moving average of $74.11 and a 200 day simple moving average of $69.24.

Corteva (NYSE:CTVA - Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 EPS for the quarter, hitting analysts' consensus estimates of $0.22. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The firm's revenue was down 1.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.32 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Equities research analysts expect that Corteva, Inc. will post 2.96 EPS for the current fiscal year.

Corteva Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Monday, March 2nd will be paid a $0.18 dividend. The ex-dividend date is Monday, March 2nd. This represents a $0.72 annualized dividend and a dividend yield of 0.9%. Corteva's payout ratio is 45.57%.

About Corteva

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.